Ardent Health Inc

ARDT broke above its June consolidation but has since drifted sideways near its short-term EMAs without decisive follow-through. The 9, 20, and 50 EMAs are flat to slightly rising, holding price support, while RSI and Options Score remain neutral, signaling no exhaustion. Medium-term bias stays bullish within a Stage 3 regime, but timing is unfavorable until renewed momentum emerges. A pullback to the 10.8–10.9 EMA zone offers a more defined engagement area. The long-term 200-day SMA is still declining, underscoring structural risk.

• ↑Operating cash flow surged 68% YoY to $197M in Q2 2026.
• ↑Repurchased $13M of stock in Q2 with $34M authorization remaining.
• ↓Q2 surgeries declined 2.9%, highlighting demand volatility.